Suma Sri Chennnapragada

Spent the weekend refreshing updates from # ASCO2025 It was wonderful to have the “Best of ASCO” meeting in Shreveport this year ! Thanks to the @binaytara @binayshah foundation for this event! Their work on cancer disparities is truly inspiring…

🚨 Wow! #ASCO25 @ASCO was absolutely massive! 10 @NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert

Concerning trends of early onset colon cancer Read our study here : tandfonline.com/doi/full/10.10…

@MDHemeonc 👏 congratulations

Officially Board certified Hematologist/Medical Oncologist!!

Excited to share that I am board certified in Hematology now !! I was doubtful if I could even give the boards this year with all the other responsibilities I had but some days you just have to trust yourself and your support system 😇 #hematologyboardcertified

🎉Immensely excited and proud to share with you our recent paper "Guide to Understanding and Supporting #InternationalMedicalGraduates in #Hematology #Oncology" with gratitude to my co-first author @ZiadBakouny, senior authors @DrChoueiri #DrAlfredLee, and other world-renowned co-authors, @IMG_Oncologists #IMGCoP @ASCO @JCOOP_ASCO #IMG 👉tinyurl.com/2su6r8zx 🙏🙏@TarekHaykal1 @IvyLorena_Md @ADesaiMD @AyeshaButtMD @arnabguonc @DanZhaoMD @eddy_saad @ReneeSaliby @OncBrothers @ArdeshirFatemeh @LeiDeng3 @luvpooh101 @KArnaoutakis @GIcancerDoc @RManochakian @AMarshallMD @FordePatrick @DrMMurphy @VivekSubbiah #DrChavezMacGregor @teekayowo @GlopesMd @CharuAggarwalMD @ASridharMD @DrKarineTawagi @KarunNeupaneMD @royaryam @drtulsijose @CharlesJiangMD @ASCOTECAG @FernandoDiazMD1 @KMittalmd @ziremozay @yekeduz_emre @Noha_Soror

Happy to share our latest publication! We have tried to establish some crucial risk factors for the development of non-hodgkin lymphoma in patients with autoimmune diseases @ShriyaGoyal5 @ShivaniMD @Saloni2509 @stpbystpgrowth @UpasanaAgrawal_ link.springer.com/article/10.100…

@cardiologyFIT That’s awesome Congratulations and good luck !

@SChenspeaks Doing good, Suma Had my own July first moment. Started EP fellowship.

Another year Another July 1st Some added responsibilities… Excited to step into my last year of training as a chief fellow ! #PGY6

@cardiologyFIT Thank you rahul ! Long time ! Hope you are doing good

@SChenspeaks Congratulations and good luck!

My first textbook chapter published! An important topic for all clinicians as these antibodies are becoming more And prevalent ncbi.nlm.nih.gov/books/NBK60370…

@Saloni2509 @ASCO @hemeoncfellow @arpita_pawa 👏👏

"Honored to present two posters at #ASCO2024! Exciting discussions and insights into ‘RCC in Post Transplant patients’ and ‘Asciminib related cardiovascular side effects’. Grateful for the opportunity to contribute to the ongoing advancements in oncology. @ASCO @hemeoncfellow

@stpbystpgrowth @AshwiniG2188 They sure do 😋

A trip to chicago is not complete without a stop at the good old Nando’s 😉

Day 2 at @ASCO 2024 Some exciting plenary sessions and catching up with friends from all over! It’s great to see pathbreaking research in lung cancer which has always starved for new treatments! @ShivaniMD @KalantriShreyas

Day 1 at @ASCO 2024! Career sessions and lots of learning

@UGrewalMD @UIowaCancer Congratulations @UGrewalMD

Our team got FUNDED 💰 for (my first) phase 1 clinical trial focused on esophageal cancer 💊 🩼!! Extremely thrilled and excited for this amazing opportunity! 🏆 So looking forward to my final year of oncology fellowship. @UIowaCancer

Our work on the importance of comprehensive mutation testing in patients with Essential Thrombocythemia @nitesh_gandhi25 @SChenspeaks amjcaserep.com/abstract/index…

@ASH_hematology 2023 meeting was a great learning experience With some amazing collaborative work I had a total of 5 posters this year It was fun meeting up with friends and researchers from all over the world @RoboDoctr @ShivaniMD @Saloni2509 @ShriyaGoyal5 @arcitahanjani

Late breaking at #ASH23: The addition of subcutaneous daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and lenalidomide maintenance therapy had a significant benefit on progression-free survival among patients with multiple myeloma. Full PERSEUS trial results: